JP Morgan Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $25
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.
JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $24 to $25.